# Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

> **NCT04518293** · PHASE3 · COMPLETED · sponsor: **George Medicines PTY Limited** · enrollment: 1385 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- **DRUG:** telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
- **DRUG:** Telmisartan 20 mg/amlodipine 2.5 mg
- **DRUG:** telmisartan 40 mg/amlodipine 5 mg
- **DRUG:** Telmisartan 20 mg/indapamide 1.25 mg
- **DRUG:** telmisartan 40 mg/indapamide 2.5 mg
- **DRUG:** Amlodipine 2.5 mg/indapamide 1.25 mg
- **DRUG:** amlodipine 5 mg/indapamide 2.5 mg

## Key facts

- **NCT ID:** NCT04518293
- **Lead sponsor:** George Medicines PTY Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-09
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-09-01
- **Target enrollment:** 1385 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04518293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04518293, "Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04518293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*